NCT02941822View on ClinicalTrials.gov

Ambroxol in Disease Modification in Parkinson Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

May 31, 2018

Conditions
Parkinson Disease
Interventions
DRUG

Ambroxol

Details outlines in the intervention description.

Trial Locations (1)

Unknown

Leonard Wolfson Experimental Neurology Centre Clinical Research Facility LWENC CRF, London

All Listed Sponsors
collaborator

Cure Parkinson's

OTHER

lead

University College, London

OTHER

NCT02941822 - Ambroxol in Disease Modification in Parkinson Disease | Biotech Hunter | Biotech Hunter